← SynDRA
SILODOSIN
SynDRA canonical compound SYN0001509 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ADRA1A | ADRA1B | ADRA1D |
|---|
| Mechanism of action | adrenergic receptor antagonist |
|---|
| Indication | benign prostatic hyperplasia (BPH) |
|---|
| Disease area | urology |
|---|
All known targets
- ADRA1A
- ADRA1B
- ADRA1D
- ABCB1
- Adra1a
- KCNH2
Mechanisms of action (all sources)
- ADRA1A ANTAGONIST
- Alpha-1a adrenergic receptor antagonist
- adrenergic receptor antagonist
- ADRA1A INHIBITOR
Drug classes
- Adrenergic alpha-Antagonists
- alpha-Adrenergic Blocker
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic Antagonists
- Neurotransmitter Agents
- Urological Agents
ATC classes
- G04C · DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Cross-references
Synonyms
- urief
- urorec
- rapaflo
- silodyx
- silodoshin
- Silodosine
- Silodosina
- Kso-0400
- Rapilif
- Silodal
- Silodyx
- Urief
- Urorec
- KAD-3213
- KMD-3213
- Rapaflo
- Silodosin recordati
- KMD 3213
- Silodosin-d6
- UNII-CUZ39LUY82
- CUZ39LUY82
- CHEMBL24778
- (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide
- 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
- Q-102517
- Rapflo
- KSO-0400
- KAD 3213
- silodosine
- silodosinum
- RefChem:56683
- DTXCID3089536
- G04CA04
- MFCD00930170
- C25H32F3N3O4
- Silodosin [INN]
- Silodosin [INN:BAN]
Reported adverse events
- Dizziness
- Headache
- Nasopharyngitis
- Retrograde ejaculation
- Hypotension
Look up SILODOSIN in the interactive SynDRA portal →